Certara, Inc. (CERT) Stock Analysis
Recovery setup
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $5.88, but acceptable to hold if already in. Reason: Market cap $0.90B below $1B minimum.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia... Read more
Hold if already holding. Not a fresh buy at $5.88, but acceptable to hold if already in. Reason: Market cap $0.90B below $1B minimum. Chart setup: Death cross but MACD improving, RSI 58. Market cap $0.90B below $1B minimum. Not in investable universe. Score 4.8/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $5.88, but acceptable to hold if already in. Reason: Market cap $0.90B below $1B minimum. Chart setup: Death cross but MACD improving, RSI 58. Market cap $0.90B below $1B minimum. Not in investable universe. Target $7.58 (+28.9%), stop $5.46 (−7.7%), A.R:R 2.5:1. Score 4.8/10, moderate confidence.
Take-profit target: $7.58 (+29.0% upside). Target $7.58 (+28.9%), stop $5.46 (−7.7%), A.R:R 2.5:1. Stop-loss: $5.46.
Market cap $0.90B below $1B minimum.
Certara, Inc. trades at a P/E of N/A (forward 12.0). TrendMatrix value score: 8.3/10. Verdict: Hold.
20 analysts cover CERT with a consensus score of 3.8/5. Average price target: $9.
What does Certara, Inc. do?Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for...
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.